CCM
ONC icon

CAAS Capital Management’s BeOne Medicines Ltd ONC Stock Holding History

CAAS Capital Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,126
Closed -$1.84M – 1442
2020
Q4 		$1.84M Buy
+7,126
New +$1.96M 0.02% 507

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

CAAS Capital Management's ONC Position: Q1 2021 in Review

CAAS Capital Management sold out of BeOne Medicines Ltd (ONC) in Q1 2021, closing a stake of 7,126 shares — an estimated $1.84M sold.

CAAS Capital Management first reported a position in ONC in Q4 2020 and held it in 1 quarter. The position peaked at $1.84M in Q4 2020. 253 funds tracked by Wall St. Rank hold ONC as of Q1 2021.

  • CAAS Capital Management reported no remaining BeOne Medicines Ltd position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 7,126 BeOne Medicines Ltd shares in Q1 2021, an estimated $1.84M.
  • CAAS Capital Management first reported a position in BeOne Medicines Ltd in Q4 2020 and held it in 1 quarter.
  • CAAS Capital Management's BeOne Medicines Ltd position peaked at $1.84M in Q4 2020.
  • 253 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.